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Abstract
Regular fish/fish oil consumption is widely recommended for protection against cardiovascular diseases (CVD). Fish
and other marine life are rich sources of the cardioprotective long-chain n-3 polyunsaturated fatty acids (n-3 PUFA)
eicosapentaenoic acid (C20:5 n-3; EPA) and docosahexaenoic acid (C22:6 n-3; DHA). The lipid content and fatty acid
profile of fish, however, vary greatly among different fish species. In addition to n-3 PUFA, certain fish, such as saury,
pollock, and herring, also contain high levels of long-chain monounsaturated fatty acids (LCMUFA), with aliphatic
tails longer than 18 C atoms (i.e., C20:1 and C22:1 isomers). Compared with well-studied n-3 PUFA, limited information,
however, is available on the health benefits of marine-derived LCMUFA, particularly in regard to CVD. Our objective in
this review is to summarize the current knowledge and provide perspective on the potential therapeutic value of dietary
LCMUFA-rich marine oil for improving CVD risk factors. We will also review the possible mechanisms of LCMUFA action
on target tissues. Finally, we describe the epidemiologic data and small-scaled clinical studies that have been done on
marine oils enriched in LCMUFA. Although there are still many unanswered questions about LCMUFA, this appears to be
promising new area of research that may lead to new insights into the health benefits of a different component of fish
oils besides n-3 PUFA.
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Background
Cardiovascular disease (CVD) is the leading global cause
of death, accounting for 17.3 million deaths per year,
and is expected to grow to more than 23.6 million by
2030 [1]. According to a recent American Heart Associ-
ation analysis, 40.5% of the US population is projected
to develop some form of CVD by 2030. Indirect costs
from CVD are projected to increase by 61%, from $172
billion in 2010 to over $276 billion in 2030 [2]. In
addition, both metabolic syndrome and type 2 diabetes
confer an increased risk of coronary heart disease and
CVD [3, 4]. Thus, the mortality associated with CVD
and its rising costs illustrate the importance of CVD
prevention and the necessity for identifying effective
ways to prevent its occurrence.
Fish and fish oil consumption has been shown in mul-
tiple studies to be related to reduced incidence of sudden
cardiac death and total mortality [5–7]. Epidemiologic
studies have also found that a high intake of small and
medium size fish (mackerel, sardine, saury and eel) was
associated with a lower risk of type 2 diabetes [8].
Currently, the American Heart Association recommends
eating fatty fish, such as salmon, mackerel, and herring, at
least twice a week to promote heart health [9]. Fish and
fish oils are known to be enriched in long-chain n-3
polyunsaturated fatty acid (PUFA), such as eicosapenta-
enoic acid (C20:5 n-3; EPA) and docosahexaenoic acid
(C22:6 n-3; DHA). The therapeutic use of n-3 PUFA has
been extensively studied in a wide variety of disease
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conditions, including CVD. Potential mechanisms
whereby n-3 PUFA may reduce risk for CVD include their
beneficial effects on lipid and lipoprotein metabolism,
blood pressure, platelet function, arterial cholesterol
delivery, vascular function, and inflammatory responses
[10, 11]. Fish lipids, however, also contain varying
amounts of other unusual types of fatty acids (FA) that
are not commonly found in other food sources [12].
For example, saury [13], pollock [14], herring [15],
capelin [16], and sprats [17], as well as marine mam-
mals, such as seals and whales [18], are all enriched in
long-chain monounsaturated fatty acids (LCMUFA)
that originate from their food source, such as zooplank-
ton [19, 20] (Table 1). LCMUFA are defined as mono-
unsaturated fatty acid isomers with aliphatic tails at
least 20 carbons (Table 2), with n-11 LCMUFA as the
most abundant component. Although the n-9 LCMUFA
isomers, gondoic acid (C20:1 n-9) and erucic acid and
(C22:1 n-9), are also found in vegetable oils from mus-
tard seed and rapeseed, the major LCMUFA enriched
in marine sources are the n-11 series, gadoleic acid
(C20:1 n-11) and cetoleic acid (C22:1 n-11) [21].
Saury is one of the most highly enriched fish in
LCMUFA and is widely consumed in Asia [22]. Herring,
which is among the main commercial fish species in
European countries, and Alaska pollock, which is the
primary target for the fish industry in the United States,
are also enriched in LCMUFA [23, 24]. In addition, some
of the more widely consumed fish species, such as salmon
and cod, also contain a significant amount of LCMUFA
[14, 25]. Thus, a considerable amount of LCMUFA is
consumed from various fish sources. Although numerous
reports and reviews in recent years have showed beneficial
effects of marine-derived n-3 PUFA on CVD and many
other chronic diseases, only a limited number of studies
have focused on the health impact of the consumption of
LCMUFA. The purpose of this review is, therefore, to
describe the experimental and clinical evidence on the
effect of LCMUFA-rich diet on human health.
Incorporation of LCMUFA into plasma and organ
lipids
Compared with n-11 LCMUFA (C20:1 n-11 and C22:1
n-11), which can only be derived from the diet, n-9
LCMUFA (C20:1 n-9 and C22:1 n-9) can also be formed
by de novo synthesis, by the action of FA elongases on
oleic acid (C18:1 n-9) [26]. Although earlier animal stud-
ies showed that diets enriched in the LCMUFA isomer
C22:1 caused a transient lipidosis in some organs, lipid-
osis disappeared upon continued feeding, possibly due
Table 1 Fatty acid profile of marine sources enriched in LCMUFA
FA (%) Calanus Oil Seal Oil Whale Oil Herring oil Mackerel oil Saury oil Pollock oil
Reference [19] [59] [59] [15] [30] [13] [14]
C14:0 9.1 6.5 5.3 9.8 8.0 N.S. N.S.
C16:0 7.4 10.1 7.9 14.3 13.9 9.2 9.8
C18:0 N.S. 1.4 1.8 1.9 2.6 1.7 1.7
Σ SFA 18.2 18 15.3 26.1 29.8 10.9 11.5
C16:1 16.2 16.8 8.8 5.0 4.2 2.9 6.1
C18:1 3.3 22.9 16.3 8.4 14.9 5.8 14.3
C20:1 n-11 N.S. N.S. 1.7 12.2b 12.2 12.1 9.1
C20:1 n-9 12.2 10.9 15.3 0.8 3.1 3.3
C22:1 n-11 12.5 N.S. 9.8 20.7c 18.1 18.5 12.3
C22:1 n-9 2.5 N.S. 0.9 1.0 1.6
Σ LCMUFAa 27.2 10.9 27.7 32.9 31.1 34.7 26.3
Σ MUFA 58.9 50.6 54.8 46.4 50.2 43.4 46.7
C18:2 n-6 0.6 1.8 1.4 1.7 1.8 1.6 1.3
C20:4 n-6 N.S. 0.5 0.3 N.S. N.S. 0.6 N.D.
Σ n-6 PUFA 0.6 2.3 2 1.7 1.8 2.2 1.3
C18:3 n-3 0.1 0.6 1.2 1.1 1.5 1.2 1.1
C20:5 n-3 8.6 9 4.3 6.3 5.4 1.6 1.2
C22:5 n-3 N.S. 5.2 2.3 N.S. 0.4 6.1 10.3
C22:6 n-3 9.3 11.7 7.9 6.8 7.8 11.8 7.9
Σ n-3 PUFA 19.5 26.5 18.7 17.3 16.5 20.7 20.5
aLCMUFA is shown as the sum of C20:1 and C22:1 isomers; bpresented as C20:1; cpresented as C22:1. LCMUFA long-chain monounsaturated fatty acid, MUFA
monounsaturated fatty acid, N.D. not detected, N.S. not shown, PUFA polyunsaturated fatty acid, SAF saturated fatty acid
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to increased activity of peroxisomal β-oxidation [27]. A
recent animal feeding study from our group showed that
the LCMUFA-rich diet resulted in a small but significant
increase in each LCMUFA isomer in plasma and vital
organs, such as liver, skeleton muscle, and duodenum,
with the most prominent changes occurring in adipose
tissues [28]. Similarly, generally MUFA is also enriched
in adipose tissue [29], because of either its greater en-
trance into adipocytes or because of a putative desatur-
ation process of saturated FA by the steraoyl desaturase
(SCD1). Compared with organ levels of LCMUFA, less
LCMUFA are found in plasma, suggesting a possible
rapid metabolism of these monoenoic acids. This hy-
pothesis is supported by human studies. An early study
conducted by von Lossonczy et al. [30] showed that the
plasma LCMUFA was not detected in serum lipid frac-
tions, such as TG and sterol esters, in healthy subjects
fed mackerel diet for 3 weeks, despite of high content of
LCMUFA (31% (w/w)) in the mackerel fat. In another
study, plasma chylomicron cetoleic acid (C22:1 n-11)
levels peaked at hour 3–6 (10.6% ± 4.5), and dropped to
near baseline (0.03% ± 0.08) at 12–24 h (0.13% + 0.05)
after fasting subjects consumed 50 ml of herring oil
enrich in LCMUFA (22.3% cetoleic acid) [31]. We also
found that a single serving of LCMUFA-rich saury diet
(11 g of LCMUFA and 5.6 g of n-3 PUFA in the saury
meal) resulted in a rapid 13-fold increase in plasma
LCMUFA levels 2 h after the meal and then declined
sharply [32]. The postprandial plasma levels of LCMUFA
dropped significantly at 24 h, although it was still signifi-
cantly higher than baseline (0.37% ± 0.02 at 24 h vs.
0.17% ± 0.05 at baseline, p < 0.01). In contrast, plasma
n-3 PUFA levels peaked at 6 h and increased only by
1.1-fold after saury ingestion and then gradually de-
clined. At 24 h post-ingestion, plasma n-3 PUFA levels
rose by 67% compared with the pre-ingestion values
(10% ± 0.6 at 24 h vs. 6% ± 0.7 at baseline, p < 0.01).
Overall, these results suggest that different metabolic
pathways may be responsible for the mobilization rates
of different fish oil-derived fatty acids. In general, it ap-
pears that LCMUFA are rapidly catabolized and thus do
not accumulate in plasma. Braekkan et al. also reported
that no direct relation was found between the dietary fat
types and fatty acid deposition [33]. In contrast to fatty
acids with shorter chain length and higher unsaturation that
seemed to increase plasma deposition, LCMUFA had
decreased plasma deposition probably due to rapid
metabolism through retroconversion and or chain
elongation [27].
Animal studies
LCMUFA-rich marine oil diet and CVD risk factors
Several animal studies have reported that LCMUFA–rich
marine oil, improved CVD risk factors. A summary of
these findings and the possible mechanism of action of
LCMUFA on target tissues is shown in Fig. 1. For
example, a high-fat fed C57BL/6J mice treated with
saury oil for either short term (6-weeks) or long term
(18-weeks) showed major improvements in several
features related to metabolic syndrome [28, 34]. A 10%
(w/w) of supplementation of saury oil (equivalent to
appropriate 3.5% (w/w) LCMUFA) in a high-fat diet
ameliorated diet-induced hyperinsulinemia and dyslipid-
emia compared to high-fat control diet. Saury oil diet
resulted in a significant increase in LMCUFA levels, es-
pecially n-11 LCMUFA, in plasma and in organs (liver,
adipose tissues and skeleton muscle). Suppression of
genes related to adipogenesis and induction of genes
involved in fatty acid oxidation and insulin signaling
with saury oil supplementation were also associated with
improvements in glucose and lipid metabolism. Simi-
larly, 6-week treatment of 15% (w/w) of LCMUFA-rich
pollock oil (equivalent to appropriate 3.9% (w/w)
LCMUFA) in diet-induced obese mice increased organ
Fig. 1 Beneficial effects of marine LCMUFA-rich diet. LCMUFA
suppressed lipogenesis and inflammation, and promoted fatty acid
oxidation PPAR signaling pathway at gene expression level in liver and
white adipose tissues. In the vessels, LCMUFA suppressed lipid
deposition and macrophage accumulation. LCMUFA also improved
plasma lipid and cytokine profiles, as well as n-3/n-6 PUFA ratio. All
these mechanisms accounted for the LCMUFA-mediated improvement
in lipid metabolism, insulin sensitivity, and atherosclerosis
Table 2 List of most common LCMUFA isomers found in
marine source
Common name Lipid name Systematic name
Gadoleic acid C20:1 n-11 cis-9-icosenoic acid
Cetoleic acid C22:1 n-11 cis-11-docosenoic acid
Gondoic acid C20:1 n-9 cis-11-eicosaenoic acid
Erucic acid C22:1 n-9 cis-13-docosenoic acid
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levels of LCMUFA, and suppressed the rise in proathero-
genic LDL-cholesterol without decreasing anti-atherogenic
levels of HDL-cholesterol [35]. An attenuation in hepatic
steatosis and a down-regulation of hepatic genes involved
in cholesterol and lipid synthesis by the pollock oil diet
most likely contributed to these findings. In addition, Gab-
rielsson et al. fed LDLR-deficient mice herring fillet or beef
for 16 weeks, and investigated the effect of dietary herring
on plasma lipid levels and atherosclerosis [36]. The major
differences in fatty acid composition between herring and
beef diet were the enrichment of long-chain n-3 PUFA
(herring diet: 4.9% EPA and DHA vs. beef diet: Not
Detected) and LCMUFA (herring diet: 3.4% C20:1 and
C22:1 vs. beef diet: Not Detected) in herring diet. They
showed that herring diet compared to the beef diet led to
lower plasma triglyceride (TG) and Very-low-density
lipoprotein (VLDL)-cholesterol levels and higher plasma
High-density lipoprotein (HDL)-cholesterol levels, along
with less atherosclerotic lesions. A recent study by Eilertsen
et al. used marine mammal oil, and the results showed that
atherogenesis was inhibited in apoE-deficient mice fed diet
supplemented with 1% of seal oil combined with extra vir-
gin oil (EVO/n-3), compared with diet supplemented with
1% corn oil or without any supplement (control). Besides
long-chain omega-3 PUFA, such as EPA and DHA, the
EVO/n-3 oil was also enriched in LCMUFA (C20:1 in
EVO/n-3 diet was 2-fold higher than that in control or corn
oil-rich diet), suggesting that in addition to n-3 PUFA that
the LCMUFA in the seal oil may also contribute to the
protection against atherosclerosis [37]. In addition to the
studies using LCMUFA-rich fish oils or marine mammal
oils, some studies also focused on the health impact of
zooplankton-derived oils. Calanus finmarchicus is the most
abundant herbivorous zooplankton that that are enriched
in both n-3 PUFA and LCMUFA [38]. Several studies
showed beneficial effect of dietary Calanus oil in CVD risk,
such as reducing atherosclerotic plaque formation, abdom-
inal fat accumulation and hepatic steatosis, and improving
glucose tolerance in mice through multiple mechanisms,
including regulation of inflammatory response-associated
gene expression in livers and adipose tissues [39–41].
Nevertheless, because these marine oils also contain con-
siderable amounts of n-3 PUFA and intake of these marine
oils increased plasma and organ levels of EPA and DHA,
one cannot exclude the possibility that the benefit from this
diet was only due to n-3 PUFA consumption. Further
animal studies using purified LCMUFA are necessary to
better understand the functional relationships between
dietary LCMUFA and CVD risk factors.
Dietary LCMUFA concentrate oil and CVD risk factors
Only a few studies have been conducted to investigate
the impact of dietary marine-derived LCMUFA on
metabolic disorders (Table 3). Our group concentrated
LCMUFA (LCMUFA: 60~70%; total n-3 PUFA: <1%) from
saury oil and estimated its effect in animal models on vari-
ous metabolic and inflammatory parameters, as well as
atherosclerosis. A 5% (w/w) LCMUFA supplemented
western diet for 6-weeks in diet-induced obese mice
improved insulin resistance and reduced blood lipids
compared to western diet control. These changes were
attributed to favorable alterations in the mRNA level of
genes related to glucose/lipid metabolism and inflamma-
tion [42]. Similarly, chow diet supplemented with 4% (w/w)
LCMUFA concentrate for 8-weeks in type II diabetic mice
alleviated several metabolic parameters compared to
soybean oil diet [43]. Along with reduced hyperin-
sulinemia, hyperleptinemia, and adipocyte size, the
LCMUFA diet down-regulated inflammatory genes, and
up-regulated Pparg and its target genes. Pparg, an iso-
form in the PPAR family, is known to play a crucial role
in regulating adipocyte differentiation and fatty acid
metabolism [44, 45]. The LCMUFA-induced improve-
ments in diabetes may, therefore, be possibly related to
the upregulation of Pparg and its target genes. Upregu-
lation of PPAR family genes by dietary LCMUFA was
also observed in ApoE-deficient mice and LDLR-
deficient mice [46]. Both a higher dose 5% (w/w) or a
lower dose 2% (w/w) LCMUFA supplementation in
western diet significantly suppressed atherosclerotic devel-
opment and upregulated key gene expression in PPAR
signaling pathway, such as Pparα and Pparγ. PPARs are
known to protect against atherosclerosis partly by regulat-
ing inflammation and enhancing ABCA1-dependent chol-
esterol efflux from macrophages in the arterial wall [47].
Our data showed that LCMUFA diet decreased plasma
inflammatory cytokine levels, and enhanced cholesterol
efflux of apoB-depleted plasma in LDLR-deficient mice
fed a LCMUFA diet by the ABCA1 transporter. It is
important to note that when 2% of olive oil enriched in
shorter-chain MUFA oleic acid was supplemented in
western diet, no significant difference was found in
atherosclerosis between the olive oil group and western
diet fed control group of LDLR-deficient mice, suggesting
that the effect of MUFA on CVD risk may differ by carbon
chain lengths. Further studies are needed to elucidate the
potential regulatory effects of individual LCMUFA
isomers on modulating PPAR levels.
Interestingly, intake of LCMUFA concentrate has been
shown to increase plasma/hepatic EPA and DHA levels
and decrease arachidonic acid (C20:4 n-6) levels,
although there were only trace levels of long-chain n-3
PUFA in the LCMUFA concentrate oil (EPA and DHA
<0.5%) [42, 43, 46]. Mobilization of PUFA after
LCMUFA diet feeding was also observed by Halvorsen
et al. [48]. In this study, a 3-week feeding of LCMUFA
concentrate oil to rats resulted in a doubling of the EPA/
arachidonic acid ratio in liver and plasma phospholipids
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compared to lard diet. Arachidonic acid, one of the
major components of n-6 PUFA that competes with n-3
PUFA for several physiological processes, is reported to
increase inflammatory signals possibly through one of its
myriad metabolites and has been associated with meta-
bolic/cardiovascular disorders [49]. A low n-3/n-6 PUFA
ratio has also been shown to promote the pathogenesis
of many diseases, including cardiovascular disease and
inflammatory diseases [50]. Thus, LCMUFA-rich marine
oils may also be beneficial in regard to CVD by their
effect on circulating and organ levels of PUFA.
Comparison of the effect of dietary n-3 PUFA-rich and
LCMUFA-rich marine oils on CVD risk factors
Both long-chain n-3 PUFA and LCMUFA are the main
fatty acid fractions in some fish species and marine
mammals, and the individual actions of n-3 PUFA and
LCMFUA need to be better understood. To date, only a
few studies have compared the effect of marine-derived
n-3 PUFA and LCMUFA on CVD risk factors in animal
models. In two earlier studies [48, 51], rats were fed lard
diet supplemented with 6.5% of concentrated fish oil-
derived n-3 PUFA (85% EPA and DHA), LCMUFA (80%
C20:1 and C22:1), or not (control) for 3-weeks. The
peroxisomal β-oxidation in livers from mice in both n-3
PUFA and LCMUFA diet groups were significantly
enhanced compared with that of the lard diet group,
with the n-3 PUFA diet group showing a greater
increase. Previous studies also showed stimulatory effect
of LCMUFA-rich oils on peroxisomal β-oxidation in the
heart [52]. FA are known to be degraded by both mito-
chondrial (primarily FAs with carbon chain length
shorter than C20) and peroxisomal β-oxidation (primar-
ily FAs with carbon chain length greater than C20), and
these two pathways are partly controlled at the gene
regulatory level [53, 54]. The nuclear receptor PPARα
has been reported to have an important role in the
transcriptional control of genes involved in cardiac FA
oxidation, and long-chain FA, such as EPA and DHA
and their derivatives, serve as PPARα ligands [55, 56].
The upregulation of Pparα by dietary n-3 PUFA or
LCMUFA, therefore, may account for the stimulation of
peroxisomal FA oxidation. In another study investigating
metabolism differences between dietary fish oil and seal
oil, plasma and hepatic lipids and lipid peroxidation
levels were markedly lower in hamsters fed seal oil-rich
diet for 4-weeks compared to those fed fish oil [57]. One
of the distinct differences between fish oil and seal oil
was the fatty acid composition. Seal oil contains much
higher levels of MUFA compared to fish oil (50.6% of
MUFA in seal oil vs. 22.2% in fish oil). Because a consid-
erable amount of shorter-chain MUFA (C18:1 n-9 and
Table 3 Summary of animal studies using LCMUFA concentrate oil (LCMUFA: 58~80%; n-3 PUFA: <0.1%)
Ref. Animal model Diet Term Health outcomes of LCMUFA diet
(p < 0.05 vs. control)
[42] Diet-induced obese mice C57BL/6J
(n = 10/group)
Hight-fat diet
(42% energy from fat)
supplemented 5% LCMUFA
or not (control)
6 weeks Plasma TC, LDL-C reduction;
Insulin resistance improvement;
Anti-inflammation (Decreased plasma
resistin levels and inflammatory gene
expressions);
Increase in n-3 PUFA and decrease in
n-6 PUFA in liver
[43] Spontaneous Type II diabetic
mice KKAy (n = 10/group)
Chow diet
supplemented 4% LCMUFA
or soybean oil (control)
8 weeks Plasma TC, FFA, insulin and leptin reduction;
Adipocyte size reduction;
Upregulation of Pparg family genes
[46] ApoE-KO mice (n = 13-15/group) Western diet
(42% energy from fat)
supplemented 5% LCMUFA
or not (control)
12 weeks Plasma TC, LDL-C reduction;
Atherosclerotic lesion area reduction;
Anti-inflammation (Decreased macrophage
and inflammatory gene expression in aorta);
Upregulation of PPAR signaling
pathway in liver
[46] LDLR-KO mice (n = 12/group) Western diet
(42% energy from fat)
supplemented 2% LCMUFA,
olive oil, or not (control)
12 weeks No change in plasma lipid levels;
Atherosclerotic lesion area reduction;
Anti-inflammation (Decreased plasma
inflammatory cytokine levels and in aorta);
Upregulation of PPAR signaling pathway in liver;
Increase in n-3 PUFA and decrease in arachidonic
acid (C20:4 n-6) in plasma and liver
[48] Diet-induced obese Wistar
rats (n = 6/group)
High-fat diet
(42% energy from fat)
supplemented 6.5% LCMUFA,
n-3 PUFA, or not (control)
3 weeks No change in plasma lipid levels;
Stimulation of peroxisomal β-oxidation in liver;
Increase in n-3 PUFA and decrease in
arachidonic acid (C20:4 n-6) in plasma and liver
FFA free fatty acids, KO knockout, LCMUFA long-chain monounsaturated fatty acids, LDL-C LDL cholesterol, PPAR peroxisome proliferator-activated receptor, PUFA
polyunsaturated fatty acids, TC total cholesterol
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C16:1 n-7) were also contained in the MUFA fraction of
seal oil besides LCMUFA (C20:1 n-9), it will be import-
ant to delineate the individual effects of each FA on the
regulation of lipid metabolism and oxidative stress.
We recently analyzed the plasma lipid change in mice
fed a lard diet supplemented with n-3 PUFA (97% EPA),
LCMUFA (57% C20:1 and C22:1), or not (control) for 8-
weeks [28]. Mice in both n-3 PUFA and LCMUFA diet
groups showed significantly lower total cholesterol in
plasma than mice in the lard diet group, and this effect
was stronger in the n-3 PUFA diet group compared with
the LCMUFA diet group. In contrast to EPA, which
decreased plasma total cholesterol with a concomitant
decrease in HDL-cholesterol, LCMUFA-rich diet did not
decrease HDL-cholesterol. Although the lipoprotein
response to LCMUFA has not been well investigated,
several studies have shown that MUFA decrease plasma
LDL-cholesterol without lowering HDL-cholesterol [58].
Nevertheless, the mechanism for the effect of LCMUFA-
rich fish oil on HDL cholesterol and other lipoprotein




To date there are no published clinical studies that have
directly evaluated the role of LCMUFA on improving
CVD risk. A small number of studies have examined the
plasma lipid and lipoprotein response to marine diets
enriched in both n-3 PUFA and LCMUFA. Osterud et
al. estimated the health impact of dietary marine oils
(whale oil, seal oil and cod liver oil) contained in typical
Eskimo diet in healthy subjects (n = 134), with whale oil
mostly enriched in LCMUFA (28% LCMUFA vs. 18.7%
n-3 PUFA) and cod liver oil mostly enriched in n-3
PUFA (28.7% n-3 PUFA vs. 18.2% LCMUFA) [59]. After
10-week intake of various oils (15 ml/day), whale oil
consumption had the most profound effect on increasing
plasma HDL-cholesterol compared to the baseline, along
with a significant increase in plasma LCMUFA levels by
80% compared to control (no oil). In contrast, plasma
TG decreased significantly only in cod liver oil group
compared to the control, with most profound increased
in plasma n-3 PUFA levels. In another study using
marine mammal oil, healthy subjects (n = 19) consumed
20 g of vegetable oil (control) or seal oil enriched in
omega-3 PUFA (26.2% (w/w) vs. 0.3% in control) and
LCMUFA (15.2% (w/w) vs. 0.3% in control) for 42 days.
Compared with control, the seal oil supplement group
showed a modest beneficial effect on fibrinogen and
protein C levels [60]. Similarly, a study by Bakken et al.
showed that 2-week seal oil supplement (15 ml per day)
attenuated microbubble-induced platelet aggregation
compared with baseline in 11 healthy volunteers [61].
Besides marine mammal oils, several studies investigated
the association between dietary fish oils enriched in n-3
PUFA and LCMUFA and CVD risk. A cross-over study
by Childs and associates investigated the lipoprotein
response to different types of fish oils (EPA-rich pollock
oil and DHA-rich tuna and salmon blend oils) in healthy
subjects [62]. Normolipidemic subjects consumed a diet
enriched in butter fat, pollock oil, or either tuna or
salmon-blend oil for 3-weeks, with a 4-week washout
period between treatments. Interestingly, although both
tuna and salmon blend oils used in the study were
enriched in DHA (14.4% (w/w) in tuna oil, 9.6% in
salmon blend oil, and 2.5% in butter), HDL responded
differently in the tuna and salmon diet groups. Com-
pared with butter diet, total HDL-cholesterol and HDL2-
cholesterol decreased on the tuna diet, whereas there
was no change in HDL-cholesterol and HDL2-choles-
terol increased slightly in the salmon diet group. One
factor that could possibly be responsible for this differ-
ence was the higher amount of LCMUFA in salmon
blend oil (25% LCMUFA in salmon blend oil vs. 5.1% in
tuna oil). The authors assumed that LCMUFA, as a
MUFA family member, may act on plasma HDL simi-
larly to oleic acid, which decreases LDL-cholesterol
without decreasing HDL-cholesterol in human. Herring
fish also contains a large amount of LCMUFA in its
fillets, byproducts, or oil, and a few studies investigated
the effect of herring diet on cardiovascular disease risk
factors [63, 64]. The results showed that compared with
the diet of matched pork and chicken diets, a 6-week
herring-rich diet significantly raised HDL-cholesterol in
healthy obese subjects. Because the study focused on the
physiologic effect of n-3 PUFA contained in herring, no
data were shown on the change of plasma LCMUFA
levels after herring consumption, thus no definitive
conclusion could be drawn on the possible correlation
between plasma HDL-cholesterol and the LCMUFA
consumption. Nevertheless, an important observation
was that the content of MUFA levels was 2-fold higher
in herring dishes (~15% of energy) compared to those in
reference dishes (<5% of energy). Future studies on
LCMUFA-rich fish/fish oil diet, particularly examining
the difference in the change of lipid and lipoprotein
between LCMUFA-rich fish/fish oil diet, are necessary
to advance this field.
Observational studies
The early epidemiologic studies starting in the 1960s,
which first showed a lower incidence of coronary athero-
sclerosis and lower plasma lipid levels in certain ethnic
groups, such as Greenland Eskimos, who ate a lot of fish
[65, 66], also suggested a possible benefit from LCMUFA
consumption. Analysis of fatty acid composition of the
Eskimo food revealed that in addition to n-3 PUFA,
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dietary LCMUFA (C20:1 and C22:1) amount per day in
a typical Eskimo food was significantly higher (13-fold)
than that found in Danish control group [67]. Besides
EPA and DHA, a significantly larger proportion of circu-
lating LCMUFA (C20:1) was found in the serum of the
Greenland Eskimo living in Greenland compared to
another control group of Eskimos living in Denmark or
a reference group of Caucasian Danes [68]. Recent
studies on the association between red blood cell (RBC)
fatty acid levels and incident coronary artery disease in
the Physician’s Health Study also showed a strong
inverse association between red blood cell LCMUFA
consumption and coronary artery disease [69]. The RBC
content of C22:1 n-9 showed significant inverse associa-
tions with coronary artery disease, even after being
adjusted for RBC n-3 PUFA, saturated fatty acids, and
de novo derived MUFA (C16:1 n-7 and C18:1 n-9). A
similar inverse association was also observed between
RBC C20:1 n-9 and coronary artery disease, although
the significance disappeared after correction for multiple
comparisons. In another cohort-based analysis of dietary
FA intake and paraoxonase 1 (PON1), dietary gadoleic
aicd (C20:1 n-11) intake was positively associated with
PON1 activity in 1548 participants from Carotid Lesion
epidemiology and Risk (CLEAR) study, whereas PUFA
(EPA and arachidonic acid) were negatively associated
with PON1 activity [70]. PON1 is believed to be a key
cardioprotective factor on lipoproteins [71]. PON1 pro-
tects LDL and HDL against oxidation, and lower serum
PON1 levels were associated with higher susceptibility
of LDL oxidation and atherosclerosis risk [72]. MUFA
are also positively associated with PON1 in mammals,
and in vitro studies suggested that MUFA may bind to a
protective site on PON1 and prevents its inactivation by
oxidation [73].
Perreault et al. found that the relative percentage of
C22:1 n-9 in serum were significantly lower in metabol-
ically unhealthy obese participants compared to lean
healthy and metabolically healthy obese participants in
the Diabetes Risk Assessment study [74]. Metabolically
healthy obese individuals had BMIs similar to metabolic-
ally unhealthy obese individuals, but they had lower risk
for complications, such as inflammation, type 2 diabetes
and CVD [75, 76]. The lipid parameters and circulating
inflammatory markers in metabolically healthy obese
individuals more closely resembled that of lean healthy
individuals compared with metabolically unhealthy indi-
viduals, which may partly be attributed to the favorable
change in FA profile. Two epidemiologic studies, how-
ever, showed that higher circulating erucic acid, but not
gadoleic acid, were significantly correlated with higher
incident congestive heart failure in the population from
Cardiovascular Health Study (CHS) and the Atheroscler-
osis Risk in Communities Study, Minnesota subcohort
(ARIC), respectively [77]. It is worth noting that the
dominant constituents of marine-derived LCMUFA are
n-11 LCMUFA, which are mainly found in marine
source. The majority of LCMUFA that were examined in
the observational studies were n-9 LCMUFA, which are
generally found in both healthful and unhealthful food
sources, such as fish, mustard, vegetable oils and proc-
essed meats [77]. Furthermore, in addition to LCMUFA,
serum levels of some other fatty acids also changed in
these observational studies, thus making it difficult to
elucidate the exact relationship between LCMUFA intake
and CVD risk. In summary, the current data from observa-
tional and interventional studies on LCMUFA intake are
suggestive of a possible beneficial effect from LCMUFA on
CVD health but at this point are inconclusive.
Conclusion
Regular fish consumption is generally recommended to
promote health, and fish oil is the most commonly used
food supplement. Therefore, a more detailed understand-
ing on the effect of the minor fatty acid components of
fish oils, such as LCMUFA, on CVD risk factors is
warranted. A limited number of in vivo animal studies
have provided valuable evidence supporting the potential
for LCMUFA-rich diet in the prevention of life-style
related diseases, such as type 2 diabetes, metabolic syn-
drome, and atherosclerosis. A few human studies have
also suggested a possible link between LCMUFA-rich diet
and CVD risk protection, but further basic science and
clinical research studies are needed to firmly establish the
effect of LCMUFA-rich fish diet on atherosclerosis and
CVD risk and its mechanisms of action.
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